echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Anti gout drug R & D blank to be filled: new drug demand is strong, the share of non-medical insurance varieties is up 25%!

    Anti gout drug R & D blank to be filled: new drug demand is strong, the share of non-medical insurance varieties is up 25%!

    • Last Update: 2016-09-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medical economics report 2016-09-27 gout is a reversible disease with abnormal deposition of urate crystals Purine metabolism disorder can lead to hyperuricemia, which leads to recurrent gouty acute arthritis, gouty stone deposition, gouty stone chronic arthritis and joint deformity, often involving the kidney to cause chronic interstitial nephritis and uric acid kidney stone formation Hyperuricemia and gout are also independent risk factors for coronary heart disease and cerebral thrombosis The incidence rate of gout in the world is quite different, with 0.13% to 0.37% in Europe and the United States, and 10% in adult men in New Zealand After the 80s of last century, with the improvement of living standards, the incidence rate of gout in China has also increased rapidly Because there is no cure drug for gout, colchicine, non steroidal anti-inflammatory drugs, hormones, drugs to promote the excretion of uric acid and drugs to inhibit the synthesis of uric acid are the main anti gout drugs Colchicine and non steroidal anti-inflammatory drugs were the main drugs for acute attack, and drugs for promoting the excretion of uric acid and inhibiting the synthesis of uric acid were the main drugs for remission According to the market pattern of minenet anti gout preparations, the number of anti gout drugs has increased rapidly in the past five years, and increased by 42% in 2015 Compared with the rapid rise in the incidence rate of China's old drugs, the replacement of therapeutic drugs is lagging behind in China The market is mainly based on colchicine and benzoic bromide and Malone Benbromarone was first developed by French enterprises in 1960s, and was approved to be listed in Germany and France after 1970s Its mechanism is to block the reabsorption of uric acid by renal tubules and promote the excretion of uric acid Due to the side effects of liver and kidney, it is not the mainstream market in Europe and America, mainly in Germany, Japan, Singapore and other Asian countries Benbromarone entered China in 2000 At present, only one import enterprise and four domestic enterprises such as Chengdu Huashen produce relevant preparations There is little information in research Allopurinol and colchicine are also old drugs Allopurinol is a new molecular entity approved by FDA in 1966; colchicine appeared in FDA approval information as early as 1961 and is a compound with probenecid In China, colchicine tablets are approved by more than ten enterprises, including Taiwan Jingde Pharmaceutical Co., Ltd and domestic Yunnan Plant Pharmaceutical Co., Ltd.; allopurinol has various dosage forms, such as tablet, capsule sustained-release preparation, etc.; the production enterprises have more than ten enterprises, such as Chongqing Qingyang, but no import In the aspect of preparation innovation, allopurinol has sustained-release preparation and compound preparation formed by combination with benzbromarone, which makes the old medicine have new life In the past decade, although these drugs have been the main market force, the problems such as unsatisfactory efficacy and large side effects are always unavoidable In 2009, FDA approved Takeda's drug, non butaloric, for the treatment of gout with hyperuricemia Its mechanism is to reduce serum uric acid concentration by inhibiting the synthesis of uric acid It is the first such drug approved in the United States in nearly 40 years, and was recommended as a first-line drug in 2012 by the United States guidelines for the diagnosis and treatment of hyperuricemia gout As a new type of xanthine oxidase inhibitor, febuxostat has the same or slightly better effect of reducing uric acid as allopurinol The study shows that the drug eruption caused by febuxostat is significantly lower than allopurinol As such first-line drugs approved in the past 40 years, the feedback from the market was positive In 2015, the global sales of non Brescia were 33.2 billion yen, an increase of 23.4% year on year In May and July 2016, FDA granted temporary approval to mylan and alembic pharmaceutical non Bustan products to meet the market demand In 2013, CFDA approved Hangzhou Yangxin, Jiangsu Wanbang biology and Jiangsu Hengrui to produce non Brest tablets, and started the cultivation of the drug in the domestic market In just two years, the non bustard market has achieved a leap forward growth In the absence of medical insurance, the sales volume of sample hospitals rose directly from more than 200000 yuan in 2013 to more than 20 million yuan in 2015 The rapid increase of its market share also indicates the strong demand for new anti gout drugs in the market In December 2015, FDA approved AstraZeneca zurampuc (lesinurad) for the treatment of adult gout patients Lesinurad is a selective reabsorption inhibitor of uric acid, which can reduce the production of uric acid and increase the excretion of uric acid As the first selective uric acid reabsorption inhibitor in the United States, it can be combined with xanthine oxidase inhibitors, such as generic allopurinol or non bustard, providing a new treatment option for patients In February this year, zurampuc was also approved by the European Union Compared with the xanthine oxidase inhibitors allopurinol and uroic, they both play a role by reducing the content of uric acid in the blood Krystexxa, which was listed in 2010, is an enzyme that can convert uric acid into harmless chemicals and excrete it in the urine, thus reducing the content of uric acid After krystexxa went public, the company had to apply for bankruptcy protection due to the low sales volume, which led to the withdrawal in the EU market Conclusion: some organizations predict that with the launch of new anti gout drugs, the global anti gout drug market will usher in rapid development However, in China, except colchicine and non - bustard, three other anti - gout drugs approved by Europe and America in recent years have not been listed in China or declared by enterprises How to keep up with the rapid development of this round has become the focus of researchers' thinking.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.